Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma (Investigational New Drugs, (2018), 36, 1, (96-102), 10.1007/s10637-017-0525-1)

Abstract

The authors would like to note an error in Figures 1 and 2 of this paper. The graph in Figure 1 incorrectly reflected the overall survival (OS), when it should have displayed the progression-free survival (PFS). The caption and median PFS values were correct. It was also noted that the upper value for the 95% CI had an error in both figures. Both graphs have been regenerated using the published PFS and OS data presented in Table 2 and the corrected 95% CIs are included. These changes do not impact the overall results of the data or the conclusions presented in the publication. We sincerely apologize for this oversight.